This site is intended only for healthcare professionals resident in the Republic of Ireland
Experience with INLYTA® extends beyond 10 years.1
INLYTA® delivered superior progression-free survival (PFS) and objective response rate (ORR) outcomes versus sorafenib in adult patients with advanced renal cell carcinoma after first-line sunitinib or a cytokine in a phase III second line setting.1,2
Adapted from INLYTA® Summary of Product Characteristics.
*Scans assessed by blinded independent radiology review.1,2
Time from randomisation to progression or death due to any cause, whichever occurs first. Cutoff date: 03 June 2011
Risk ratio is used for ORR. A risk ratio > 1 indicated a higher likelihood of responding in the axitinib arm; a risk ratio < 1 indicated a higher likelihood of responding in the sorafenib arm.
Data adapted from INLYTA® Summary of Product Characteristics.
*ORR is derived from complete and partial response as per RECIST.1,2
Data cutoff date: 31 August 2010
Real-world evidence supports clinical trial outcomes with INLYTA® in second line.1–5
Data adapted from Melichar B, et al. 2015. Matias M, et al. 2017. Facchini G, et al. 2019.
No cross trial comparisons may be made since trials were conducted using different methodologies and at different time points.
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023